Adverum Biotechnologies Inc (NASDAQ: ADVM) Could Achieve Gains In The Near Future

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Adverum Biotechnologies Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $1.97 and fluctuated between $2.9599 as its day high and $1.9600 as its day low. The current market capitalization of Adverum Biotechnologies Inc is $199.03M. A total of 15.14 million shares were traded on the day, compared to an average of 1.08M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, ADVM has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 5 SELLs from insiders. Insiders purchased 100,000 shares during that period but sold 68,099.

In the most recent transaction, Seyedkazemi Setareh sold 6,201 shares of ADVM for 1.52 per share on Sep 15. After the transaction, the Chief Development Officer now owns 47,674 company shares. In a previous transaction on Jun 07, Rubinstein Linda M bought 100,000 shares at 1.45 per share. ADVM shares that Chief Financial Officer owns now total 100,000.

Among the insiders who sold shares, Fischer Laurent disposed of 41,239 shares on Mar 15 at a per-share price of $0.78. This resulted in the CEO, President and Director holding 692,141 shares of ADVM after the transaction. In another insider transaction, Soparkar Peter sold 13,360 shares at $0.78 per share on Mar 15. Company shares held by the Chief Operating Officer now total 265,891.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for ADVM in the last 3 months, the mean price target is $4.20 with high estimates of $6.00 and low estimates of $3.00. In terms of 52-week highs and lows, ADVM has a high of $2.82 and a low of $0.61.

As of this writing, ADVM has an earnings estimate of $Adverum Biotechnologies, Inc. per share for the current quarter. EPS was calculated based on a consensus of Archer-Daniels-Midland Company estimates, with a high estimate of $GLOBAL DEVELOPMENT INC per share and a lower estimate of $Advantage Solutions Inc.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ADVM’s latest balance sheet shows that the firm has $305.19M in Cash & Short Term Investments as of fiscal 2021. There were $102.99M in debt and $21.32M in liabilities at the time. Its Book Value Per Share was $1.02, while its Total Shareholder’s Equity was $316.19M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ADVM is Buy with a score of 4.67.

Most Popular

Related Posts